KAT6A and breast carcinoma: The KAT6A/B inhibitor PF-07248144 is currently being validated for safety, tolerability, and clinical efficacy in combination with either Fulvestrant, letrozole + palbociclib, or PF-07220060 + Fulvestrant in patients with advanced or metastatic solid tumors, including breast cancer (NCT04606446, Table 3).